Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is c...
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT05228470
- Locations
- ๐จ๐ณ
Shenzhen Second People's Hosptial, Shenzhen, Guangdong, China
๐จ๐ณHematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
๐จ๐ณFujian Medical University Union Hospital, Fuzhou, Fujian, China
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 761
- Registration Number
- NCT05020236
- Locations
- ๐บ๐ธ
MSK Bergen, Montvale, New Jersey, United States
๐บ๐ธMSK Commack, Commack, New York, United States
๐บ๐ธMSK Westchester, Harrison, New York, United States
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT05014412
- Locations
- ๐บ๐ธ
UF Health Shands Hospital Pharmacy Investigational Drug Service - Main, Gainesville, Florida, United States
๐บ๐ธMayo Clinic Hospital, Phoenix, Arizona, United States
๐บ๐ธMayo Clinic, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.